Diagnosis for Chinese patients with light chain amyloidosis: a scoping review

References

• Merlini G. AL amyloidosis: from molecular mechanisms to targeted therapies. Hematology Am Soc Hematol Educ Program. 2017;2017(1):1–12. doi: 10.1182/asheducation-2017.1.1.
   PubMed Web of Science ®Google Scholar
• Nienhuis HL, Bijzet J, Hazenberg BP. The prevalence and management of systemic amyloidosis in Western countries. Kidney Dis . 2016;2(1):10–19. doi: 10.1159/000444206.
   Google Scholar
• Maurer MS, Elliott P, Comenzo R, et al. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation. 2017;135(14):1357–1377. doi: 10.1161/CIRCULATIONAHA.116.024438.
   PubMed Web of Science ®Google Scholar
• Hou H-A, Tang C-H, Goh CH, et al. A population-based cohort study of the epidemiology of light-chain amyloidosis in Taiwan. Sci Rep. 2022;12(1):15736. doi: 10.1038/s41598-022-18990-3.
   PubMedGoogle Scholar
• Seo SR, Jang SY, Lee GY, et al. Prevalence of amyloidosis in korea. Orphanet J Rare Dis. 2017;12(1):152. doi: 10.1186/s13023-017-0705-2.
   PubMedGoogle Scholar
• Quock TP, Yan T, Chang E, et al. Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv. 2018;2(10):1046–1053. doi: 10.1182/bloodadvances.2018016402.
   PubMed Web of Science ®Google Scholar
• Aimo A, Buda G, Fontana M, et al. Therapies for cardiac light chain amyloidosis: an update. Int J Cardiol. 2018;271:152–160. doi: 10.1016/j.ijcard.2018.05.018.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Palladini G, Minnema MC, et al. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med. 2021;385(1):46–58. doi: 10.1056/NEJMoa2028631.
   PubMed Web of Science ®Google Scholar
• Kaufman GP, Cerchione C. Beyond andromeda: improving therapy for light chain amyloidosis. Front Oncol. 2020;10:624573. doi: 10.3389/fonc.2020.624573.
   PubMed Web of Science ®Google Scholar
• Palladini G, Kastritis E, Maurer MS, et al. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood. 2020;136(1):71–80. doi: 10.1182/blood.2019004460.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Rousakis P, Kostopoulos IV, et al. Consolidation with a short course of daratumumab in patients with AL amyloidosis or light chain deposition disease. Amyloid. 2021;28(4):259–266. doi: 10.1080/13506129.2021.1971192.
   PubMed Web of Science ®Google Scholar
• Staron A, Zheng L, Doros G, et al. A 40-Year natural history study of overall survival and primary causes of death in systemic light chain (AL) amyloidosis. Blood. 2021;138(Supplement 1):155–155. doi: 10.1182/blood-2021-151804.
   Google Scholar
• Parkin S, Seidman MA, Davis M, et al. Clinical characteristics and outcome of patients with wild-type transthyretin and AL cardiac amyloidosis confirmed by mass spectrometry. Blood. 2018;132(Supplement 1):3126–3126. doi: 10.1182/blood-2018-99-115317.
   Google Scholar
• McCausland KL, White MK, Guthrie SD, et al. Light chain (AL) amyloidosis: the journey to diagnosis. Patient. 2018;11(2):207–216. doi: 10.1007/s40271-017-0273-5.
   PubMedGoogle Scholar
• Schulman A, Connors LH, Weinberg J, et al. Patient outcomes in light chain (AL) amyloidosis: the clock is ticking from symptoms to diagnosis. Eur J Haematol. 2020;105(4):495–501. doi: 10.1111/ejh.13472.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Merlini G. Immunoglobulin light chain systemic amyloidosis. Cancer Treat Res. 2016;169:273–318.
   PubMedGoogle Scholar
• Fotiou D, Dimopoulos MA, Kastritis E. Systemic AL amyloidosis: current approaches to diagnosis and management. Hemasphere. 2020;4(4):e454. doi: 10.1097/HS9.0000000000000454.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Dispenzieri A. Systemic amyloidosis recognition, prognosis, and therapy: a systematic review. Jama. 2020;324(1):79–89. doi: 10.1001/jama.2020.5493.
   PubMed Web of Science ®Google Scholar
• Vaxman I, Gertz M. When to suspect a diagnosis of amyloidosis. Acta Haematol. 2020;143(4):304–311. doi: 10.1159/000506617.
   PubMed Web of Science ®Google Scholar
• Hester LL, Gifkins DM, K MB, et al. Diagnostic delay and characterization of the clinical prodrome in AL amyloidosis among 1523 US adults diagnosed between 2001 and 2019. Eur J Haematol. 2021;107(4):428–435. doi: 10.1111/ejh.13679.
   PubMed Web of Science ®Google Scholar
• Comenzo RL, Reece D, Palladini G, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia. 2012;26(11):2317–2325. doi: 10.1038/leu.2012.100.
   PubMed Web of Science ®Google Scholar
• Merlini G, Wechalekar AD, Palladini G. Systemic light chain amyloidosis: an update for treating physicians. Blood. 2013;121(26):5124–5130. doi: 10.1182/blood-2013-01-453001.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Buadi F, Kumar SK, et al. Treatment of immunoglobulin light chain amyloidosis: mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus statement. Mayo Clin Proc. 2015;90(8):1054–1081. doi: 10.1016/j.mayocp.2015.06.009.
   PubMed Web of Science ®Google Scholar
• Muchtar E, Gertz MA, Kumar SK, et al. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood. 2017;129(15):2111–2119. doi: 10.1182/blood-2016-11-751628.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Callander NS, Adekola K, et al. Systemic light chain amyloidosis, version 2.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023;21:67–81.
   PubMedGoogle Scholar
• Vaxman I, Dispenzieri A, Muchtar E, et al. New developments in diagnosis, risk assessment and management in systemic amyloidosis. Blood Rev. 2020;40:100636. doi: 10.1016/j.blre.2019.100636.
   PubMed Web of Science ®Google Scholar
• Peters MDJ, Marnie C, Tricco AC, et al. Updated methodological guidance for the conduct of scoping reviews. JBI Evid Implement. 2021;19(1):3–10. doi: 10.1097/XEB.0000000000000277.
   PubMedGoogle Scholar
• Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467–473. doi: 10.7326/M18-0850.
   PubMed Web of Science ®Google Scholar
• Xiang L, Yuan S, Zhang X, et al. [Clinicopathological features of renal impairment in 76 cases with amyloidosis]. J Clin Pathol. 2018;38:1675–1681.
   Google Scholar
• Mao X, Deng S, Sui W, et al. Clinical analysis of patients with MGUS, primary light chain amyloidosis, multiple myeloma or multiple myeloma with concurrent amyloidosis. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021;29(3):812–818. doi: 10.19746/j.cnki.issn.1009-2137.2021.03.025.
   PubMedGoogle Scholar
• Xu Y, Cui X, Li M, et al. Cardiac manifestations of 21 patients with immunoglobulin light chain cardiac amyloidosis. Chin J Hyperten. 2021;29:371–375.
   Google Scholar
• Cheng P, Zhang Y, Li Y, et al. Clinicopathological analysis of 321 patients with renal amyloidosis. J Chin Pract Diagn Ther. 2021;35:588–591.
   Google Scholar
• Guo L, Tian Z. Clinical characteristics of patients with cardiac light-chain amyloidosis and normal left ventricular wall thickness. J Clin Cardiol. 2018;34:239–243.
   Google Scholar
• Li X, Huang S, Han P, et al. Nonenhanced chemical exchange saturation transfer cardiac magnetic resonance imaging in patients with amyloid Light-Chain amyloidosis. J Magn Reson Imaging. 2022;55(2):567–576. doi: 10.1002/jmri.27859.
   PubMed Web of Science ®Google Scholar
• Zhang L, Tang H, Cheng L, et al. Analysis of clinical and imaging features of cardiac amyloidosis: a multicenter study. J Southern Med Univ. 2014;34:295–302.
   Google Scholar
• Zhu X, Liu F, Liu Y, et al. Analysis of clinical and pathological characteristics of 28 cases with renal amyloidosis. Clin Lab. 2011;57:947–952.
   PubMed Web of Science ®Google Scholar
• Xia R, Gao F, Sun J, et al. Cardiac magnetic resonance imaging of systemic amyloidosis patients with normal left ventricular ejection fraction: an initial study. Pak J Med Sci. 2013;29(6):1300–1305. doi: 10.12669/pjms.296.3775.
   PubMed Web of Science ®Google Scholar
• Shen K, Sun W, Sun J, et al. Classification of amyloidosis by laser micro- dissection and mass spectrometry based proteomic analysis. Chin J Hematol. 2015;36:99.
   Google Scholar
• Diao X, Li J, Ouyang J, et al. Flow cytometry-based immunophenotypic analysis of primary systemic light chain amyloidosis. Oncol Lett. 2017;13(4):2691–2697. doi: 10.3892/ol.2017.5767.
   PubMed Web of Science ®Google Scholar
• Fan Y, Wu G, Zhang S. Clinical characteristics and screening indexes of light chain amyloidosis nephropathy. Chin J Pract Med. 2019;46:6–10.
   Google Scholar
• Li T, Huang X, Chen W. The significance of skin fat and rectal mucosal biopsy in the diagnosis of systemic light chain myloidosis. Chinese J Nephrol Dialysis Transplant. 2015;24:426–428.
   Google Scholar
• Zhang J, Sun J, Wu M, et al. Clinicopathological study of renal amyloidosis. Chin J Laborat Diag. 2012;16:131–133.
   Google Scholar
• Lei C, Zuo L, Wang Y, et al. The role of three-dimensional speckle tracking imaging in the diagnosis of immunoglobulin light-chain cardiac amyloidosis with normal left ventricular ejection fraction. Chin J Ultrasonogr. 2020;29:213–218.
   Google Scholar
• Zhou FD, Zhang LX, Yao Y, et al. Immunofixation electrophoresis was highly specific for the diagnosis of renal light-chain amyloidosis. Am J Med Sci. 2013;345(1):18–21. doi: 10.1097/MAJ.0b013e31824e0ec5.
   PubMed Web of Science ®Google Scholar
• Yao Y, Wang S, Zhang Y, et al. Clinicopathological correlation analysis of AL type renal amyloidosis. Chin J Nephrol. 2013;29:216–218.
   Google Scholar
• Mao X, Zhao D, Fang Q, et al. Clinicopathology of myocardial amyloidosis. Med J Peking Union Medical College Hosp. 2012;3:89–93.
   Google Scholar
• Yang J, Shi H, Xu J, et al. Clinicopathological analysis of 33 cases of primary renal amyloidosis. Modern Pract Med. 2016;28:998–999.
   Google Scholar
• Xiao H, Liu R, Yuan S, et al. Clinical and pathological features of 20 cases of renal amyloidosis. Inter J Pathol Clin Med. 2010;1:43–46.
   Google Scholar
• Wang X, Dong K, Sun L, et al. Hepatic light chain deposition disease and light chain amyloidosis clinicopathological features. Beijing Med J. 2016;38:877–879.
   Google Scholar
• Yang Y. Clinical study of renal amyloidosis and cutaneous amyloidosis in elderly and presenile patients. China Continuing Med Educ. 2015;7:78–79.
   Google Scholar
• Mei J, Shao J, Cao H, et al. Analysis of cytogenetic abnormalities in systemic light chain amyloidosis. Laborat Med Clinic. 2016;13:3463–3466.
   Google Scholar
• Zhang F, Yu X, Wang S, et al. The role of commonly used immunopathological methods in the typing of light chain renal amyloidosis. Labeled Immunoassays Clin Med. 2020;27:818–822.
   Google Scholar
• Ren L, Liu H, Xu X, et al. Diagnosis and pathological type analysis of renal amyloidosis. Chin J Nephrol. 2011;27:730–734.
   Google Scholar
• Zhang L, Wang Y, Cheng L, et al. The value of peak left ventricular long-axis systolic strain in the diagnosis of primary cardiac amyloidosis and hypertrophic cardiomyopathy. J Southern Med University. 2014;34:609–616.
   Google Scholar
• Liu D, Liu G. Analysis of clinical characteristics of 20 cases of AL amyloidosis. J Capital Med Univ. 2010;31:416–419.
   Google Scholar
• Sui Y, Jiang N, Xie L, et al. Clinicopathological analysis of 31 cases of amyloid nephropathy. Chin J Clin Exper Pathol. 2014;30:1379–1382.
   Google Scholar
• Mu X, Xiong Y, Chen J, et al. Clinical analysis of 11 cases of respiratory amyloidosis. Chin J Tubercul Respir Dis. 2013;36:88–93.
   Google Scholar
• Ren H, Lu M, Cai Q, et al. Clinicopathological analysis of 10 cases of renal amyloidosis. Military Med J Southeast China. 2011;13:348–349.
   Google Scholar
• Sa Q, Ren G, Xu X, et al. Characterization of abnormal plasma cells in systemic light chain amyloidosis. Chin J Nephrol Dialysis Transplant. 2019;28:401–405.
   Google Scholar
• Li R, Yang ZG, Xu HY, et al. Myocardial deformation in cardiac amyloid light-chain amyloidosis: assessed with 3T cardiovascular magnetic resonance feature tracking. Sci Rep. 2017;7(1):3794. doi: 10.1038/s41598-017-03699-5.
   PubMedGoogle Scholar
• Li T, Huang X, Cheng S, et al. Utility of abdominal skin plus subcutaneous fat and rectal mucosal biopsy in the diagnosis of AL amyloidosis with renal involvement. PLOS One. 2017;12(9):e0185078. doi: 10.1371/journal.pone.0185078.
   PubMed Web of Science ®Google Scholar
• Cui Q, Yu J, Shen W. The value of delayed gadolinium enhancement combined with quantitative longitudinal relaxation time imaging in the assessment of myocardial amyloidosis. Chinese Crit Care Med. 2019;31:1538–1541.
   Google Scholar
• Zhang L, Zhou X, Wang J, et al. Differentiation of light-chain cardiac amyloidosis from hypertrophic cardiomyopathy using myocardial mechanical parameters by velocity vector imaging echocardiography. Int J Cardiovasc Imaging. 2017;33(4):499–507. doi: 10.1007/s10554-016-1027-5.
   PubMed Web of Science ®Google Scholar
• Wang L, Tian Y, Lei Z, et al. Clinical analysis of immunoglobulin light chain myocardial amyloidosis. Chinese General Pract. 2020;23:3474–3478.
   Google Scholar
• Li L, Duan X, Sun Y, et al. Application value of immunohistochemical indexes in cardiac amyloidosis typing. Chin J Pathol. 2018;47:105–108.
   Google Scholar
• Sa Q, Ren G, Xu X, et al. Bone marrow plasmacytogenetic characteristics of 102 patients with systemic light chain amyloidosis. Chin J Nephrol Dialysis Transplant. 2020;29:413–419.
   Google Scholar
• Xu T, Wei Z, Chen C, et al. The value of combined abdominal wall fat and labial gland biopsy in the diagnosis of light chain amyloidosis. Chin J Clin Med. 2019;26:37–42.
   Google Scholar
• Zhai y, Song P, Li F, et al. Clinical significance of serum free light chain detection in primary systemic amyloidosis. Chin J Internal Med. 2011;50:404–407.
   PubMedGoogle Scholar
• Hu Y, Wang M, Chen Y, et al. Immunophenotypic analysis of abnormal plasma cell clones in bone marrow of primary systemic light chain amyloidosis patients. Chin Med J. 2014;127:2765–2770.
   PubMed Web of Science ®Google Scholar
• Li R, Yang ZG, Wen LY, et al. Regional myocardial microvascular dysfunction in cardiac amyloid light-chain amyloidosis: assessment with 3T cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2016;18:16. doi: 10.1186/s12968-016-0240-7.
   PubMed Web of Science ®Google Scholar
• Liu Y, Lai Y, Ma L, et al. Fluorescence in situ hybridisation combined with CD138 immunomagnetic sorting is effective to identify cytogenetic abnormalities whplosich play significant prognostic roles in chinese AL amyloidosis patients. Amyloid. 2020;27(3):208–209. doi: 10.1080/13506129.2020.1723538.
   PubMed Web of Science ®Google Scholar
• Howie AJ, Brewer DB, Howell D, et al. Physical basis of colors seen in Congo red-stained amyloid in polarized light. Lab Invest. 2008;88(3):232–242. doi: 10.1038/labinvest.3700714.
   PubMed Web of Science ®Google Scholar
• Guselnikova VV, Antimonova OI, Fedorova EA, et al. A novel method for amyloid detection in human tissue load using a fluorescent dye - Congo red analogue. Sovrem Tekhnologii Med. 2020;12(1):65–70. doi: 10.17691/stm2020.12.1.08.
   PubMed Web of Science ®Google Scholar
• Sjolander D, Rocken C, Westermark P, et al. Establishing the fluorescent amyloid ligand h-FTAA for studying human tissues with systemic and localized amyloid. Amyloid. 2016;23(2):98–108. doi: 10.3109/13506129.2016.1158159.
   PubMed Web of Science ®Google Scholar
• Salameh OK, Darok MC, Kane JA, et al. Unusual case of nephrotic syndrome from light chain amyloidosis in a 37-year-old patient. Cureus. 2021;13(9):e18120. doi: 10.7759/cureus.18120.
   PubMedGoogle Scholar
• Murray DL, Dasari S. Clinical mass spectrometry approaches to myeloma and amyloidosis. Clin Lab Med. 2021;41(2):203–219. doi: 10.1016/j.cll.2021.03.003.
   PubMed Web of Science ®Google Scholar
• Verine J, Mourad N, Desseaux K, et al. Clinical and histological characteristics of renal AA amyloidosis: a retrospective study of 68 cases with a special interest to amyloid-associated inflammatory response. Hum Pathol. 2007;38(12):1798–1809. doi: 10.1016/j.humpath.2007.04.013.
   PubMed Web of Science ®Google Scholar
• Novak L, Cook WJ, Herrera GA, et al. AL-amyloidosis is underdiagnosed in renal biopsies. Nephrol Dial Transplant. 2004;19(12):3050–3053. doi: 10.1093/ndt/gfh503.
   PubMed Web of Science ®Google Scholar
• Prokaeva T, Spencer B, Sun F, et al. Immunoglobulin heavy light chain test quantifies clonal disease in patients with AL amyloidosis and normal serum free light chain ratio. Amyloid. 2016;23(4):214–220. doi: 10.1080/13506129.2016.1219715.
   PubMed Web of Science ®Google Scholar
• Palladini G, Russo P, Bosoni T, et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem. 2009;55(3):499–504. doi: 10.1373/clinchem.2008.117143.
   PubMed Web of Science ®Google Scholar
• Katzmann JA, Abraham RS, Dispenzieri A, et al. Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem. 2005;51(5):878–881. doi: 10.1373/clinchem.2004.046870.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th international symposium on amyloid and amyloidosis, tours, France, 18–22 april 2004. Am J Hematol. 2005;79(4):319–328. doi: 10.1002/ajh.20381.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Kyle R, Merlini G, et al. International myeloma working group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009;23(2):215–224. doi: 10.1038/leu.2008.307.
   PubMed Web of Science ®Google Scholar
• Gillmore JD, Wechalekar A, Bird J, et al. Guidelines on the diagnosis and investigation of AL amyloidosis. Br J Haematol. 2015;168(2):207–218. doi: 10.1111/bjh.13156.
   PubMed Web of Science ®Google Scholar
• Hwa YL, Fogaren T, Sams A, et al. Immunoglobulin light-chain amyloidosis: clinical presentations and diagnostic approach. J Adv Pract Oncol. 2019;10:470–481.
   PubMedGoogle Scholar